Solid tumours have different amounts of oxygen and low levels (hypoxia) are associated with resistance to treatment and a poor prognosis. Around half of solid tumours will be hypoxic, which reduces the efficacy of surgery, radiotherapy, and many chemotherapeutic agents. Conversely, there is likely to be an enriched population with low tumour hypoxia with increased efficacy.
There is currently no way to measure the level of hypoxia in tumours in routine clinical practice.
ManTRa DX has developed tumour-site-specific gene expression signatures to assess hypoxia which has the potential to deliver major advances in personalised cancer medicine. The signatures can be used as the basis for a Companion Diagnostic (CDx) to stratify patients for treatment and as a mechanism to direct therapy choices.
The initial offering will be to demonstrate the feasibility of a clinical service delivery for head and neck cancer (ManTRa DX H+N) in collaboration with the Greater Manchester Healthcare Infrastructure. This has potential to provide benefit to hundreds of cancer patients, developing an exemplar for a translational pipeline for world-class research. Clinical trials often fail due to unselected patient recruitment, and as such ManTRa DX will also target (Bio)Pharmaceutical Companies.
If you are interested in discussing our technology further, then please register your interest or send us an enquiry.